CASE REPORT

Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas

Mohamed Sharafeldeen¹, Vahid Mehrmoush², Asmaa Ismail², Ahmed Zakaria², Hazem Elmansy², Walid Shahrour², Owen Prowse², Ahmed Kotb²

¹Urology Department, Alexandria University, Alexandria, Egypt; ²Urology Department, Northern Ontario School of Medicine, Thunder Bay, ON, Canada

Abstract

Over the last two decades, the treatment of metastatic RCC has changed significantly, and the role of surgery is being debated. A 50-year-old man presented with pain in his left loin. An ultrasound, followed by a CT scan, revealed a 17.5 cm left renal mass invading the left suprarenal gland, spleen, and pancreatic tail. Radical nephrectomy through chevron incision under epidural block with general anesthesia was performed. The entire mass was removed en bloc. The estimated blood loss was 300 mL, and no blood transfusions were performed. The operation took approximately 2 h. Histological examination revealed clear cell renal carcinoma with extension into the spleen, pancreatic tail, and diaphragmatic fibers with negative resection margin. The patient discharged after a 3-day uneventful hospital stay. Aggressive surgical removal of a locally invasive renal cell carcinoma is feasible and should be considered in patients with good performance status and no or minimal distant metastases.

Keywords: RCC, nephrectomy, splenectomy, pancreatectomy

Received: 21 March 2022; Accepted after revision: 22 July 2022; Published: 12 August 2022

Author for correspondence: Ahmed Kotb, Assistant Professor, Northern Ontario School of Medicine, TBRHSC, 980 Oliver Road, Thunder Bay, ON, Canada. Email: drahmedfali@gmail.com

How to cite: Sharafeldeen M, et al. Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas. J Kidney Cancer VHL. 2022; 9(3): 1–4.

Doi: https://doi.org/10.15586/jkcvhl.v9i3.231

Copyright: Sharafeldeen M, et al.

License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0

Introduction

Renal cell carcinoma (RCC) is the sixth and tenth most common cancer and accounting for 5 and 3% of all oncological diagnoses in men and women, respectively (1). Smoking, obesity, and hypertension are those risk factors strongly associated with RCC (2). Although the majority of detected lesions are small tumors, a significant proportion of patients are diagnosed with locally advanced disease, with up to 17% of patients having distant metastases at the time of diagnosis (3). The most common metastasis sites are the lung(s) (71%), lymph nodes (49%), bone (36%), liver (21%), adrenal (9%), brain (9%), pancreas (5%), pleura (4%), and thyroid (0.6%) (4). Although uncommon, isolated metastatic RCC to the pancreas or spleen has been described in the literature (4–7); however, only a few cases of RCC invading both the spleen and the pancreas have been reported (8, 9).

The treatment options for locally advanced RCC vary; including cytokine-based immunotherapy and angiogenic drugs (10–12) and aggressive surgical management (12, 13).
Some urologists strongly opposed surgical management due to the surgical challenge and the risk of recurrence (14). We present a case of locally advanced RCC with spleen and pancreatic tail invasion that was successfully treated with surgical intervention.

**Case Presentation**

A 50-year-old man presented with left loin pain. An ultrasound, followed by a CT scan, revealed a 17.5 cm left renal mass invading the left suprarenal gland, spleen, pancreatic tail, and a part of the diaphragm. He had excellent performance status and no distant metastases. Radical nephrectomy through chevron incision under epidural block with general anesthesia was performed. Over a 2-hour operation, the entire mass was removed including the kidney, adrenal gland, spleen, pancreatic tail, and diaphragmatic fibers. There was a large chain of para-aortic lymph nodes that was removed as well. The estimated blood loss was 300 mL, and no blood transfusions were required. Chest tube was inserted and removed after 48 h. Histological examination revealed Grade 4 clear cell RCC with extension into the spleen, pancreatic tail, and diaphragmatic fibers. Invasion of main renal vein and pelvicalyceal system was identified. There was neither sarcomatoid differentiation nor lymphovascular invasion. All surgical margins were negative. The resected lymph nodes were reactive with no evidence for cancer (Stage T4N0). Preoperatively, Hgb was 12 g/dL and eGFR was 85 mmol/L. On the first postoperative day, Hgb was 10 g/dL and eGFR dropped to 60 mmol/L, and these values were nearly stable during hospital admission. Four weeks post operation, the patient was reviewed. His wound had healed well, with no complications. Chest X-ray was normal. Hgb did rise to 13 g/dL, and eGFR was 80 mmol/L. The patient was discharged after a 3-day uneventful hospital stay. Six months’ CT scan did not show any evidence for cancer recurrence. We referred the patient to medical oncology team, and we agreed on surveillance, and systemic therapy was not offered. Within that short term follow-up, the patient recovered well and did not show evidence for residual or recurrent cancer. Patient's consent was obtained for data collection and publication. Ethical approval was not required. Figure 1 is a CT section showing the advanced renal mass and Figure 2 is an operative image for the resected kidney, spleen and pancreatic tail.

**Discussion**

Pancreatic and splenic metastasis of RCC generally occur in the seventh decade of life and are usually asymptomatic (6, 7, 15, 16). However, in our case, the patient was younger and aged 50 years. Splenic metastases from RCC have been reported to be more common in patients with RCC.

**Figure 1:** Axial CT abdomen showing large left renal mass infiltrating the spleen and pancreas.

**Figure 2:** The resected en bloc mass showing the kidney, spleen, and tail of pancreas.
originating in the left kidney, like our case, which is more likely via direct tumor cell spread rather than hematogenous dissemination (15, 16). Clear cell carcinoma is the most common type of renal carcinoma invading the spleen (15–17), which matches our scenario. Over the last two decades, the treatment of metastatic RCC has changed significantly, and the role of surgery is being debated. In certain clinical situations, surgical resection of metastatic RCC to the pancreas and spleen is appropriate, depending on the virulence of the primary tumor, the spread of metastatic disease, the patient’s condition, and the experience of surgeon (8, 9). The goal of resection should be to achieve clear margins while preserving as much healthy tissues as possible. It has been suggested that metastasectomy during nephrectomy may provide survival benefit over nephrectomy alone (18).

Two cases of successful laparoscopic and robotic nephrectomy were reported in the literature. The first case of RCC with invasion to spleen and pancreas was reported in 2012 in a 67-year-old woman presented with pain of the left flank and hematuria. A large mass was observed in the upper pole of the left kidney, with direct extension to the spleen and pancreatic tail, but no distant metastases in the CT scan. Laparoscopic left nephrectomy along with the distal splenopancreatectomy en bloc with estimated blood loss of 250 mL, was performed successfully in 210 min (8). This case had a follow up of 6 years and showed development of pancreatic adenocarcinoma during follow-up, and this was successfully resected. Another case reported in 2016 was of a 57-year-old woman presented with recurrent gross hematuria as well as a large left renal mass with solitary pancreatic and splenic metastasis. Following a thorough evaluation, urologists and transplant or hepatobiliary teams collaborated to perform an en bloc robot-assisted radical nephrectomy, distal pancreatectomy, and splenectomy. The left kidney, the left adrenal gland, the spleen, and the pancreatic tail were all removed. The total operating time was 194 min. The change in hemoglobin during surgery was 2.3 g/dL with no need for blood transfusion. The patient was discharged on Day 3 post operation, with no postoperative complications. The study, however, did not mention the oncological outcomes or duration for surveillance (9).

Piskorz et al. reported their experience in a similar case of RCC invading the pancreas and confirmed better survival with surgical excision. Their patient had 2 years follow-up showing no evidence of recurrence (19). Gonzalez et al. reported their experience on doing extensive surgeries of 18 patients having RCC invading liver, spleen and/or the duodenum. They confirmed that besides being safe and with no associated mortality, it, at least, allowed palliation of symptoms associated with extensive cancer invasion to surrounding organs. They had surveillance post-operative scans for up to 2 years showing no evidence for cancer recurrence (20).

Likewise, in our case, surgical management was achievable, within reasonable time and acceptable outcomes. Within a short period of surveillance (6 months), the patient did not show any evidence for cancer recurrence.

Conclusion

Surgical management for locally extensive RCC should always be considered by experienced urologists to patients with a good performance status and no or minimal distant metastases.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. https://doi.org/10.3322/caac.21551
2. Capitanio U, Coleman J, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2018;75(1):74-84. https://doi.org/10.1016/j.eururo.2018.08.036
3. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894-906. https://doi.org/10.1016/S0140-6736(15)00046-X
4. Dudani S, de Velasco G, Wells C, Gan CL, Donskov F, Porta C, et al. Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). J Clin Oncol. 2020;38(6_suppl):642. https://doi.org/10.1200/JCO.2020.38.6_suppl.642
5. Vergho DC, Loeser A, Kocot A, Spahn M, Riedmiller H. Tumor thrombus of inferior vena cava in patients with renal cell carcinoma—Clinical and oncological outcome of 50 patients after surgery. BMC Res Notes. 2012;5:5. https://doi.org/10.1186/1756-0500-5-264
6. Hiots SP, Klimstra DS, Conlon KC, Brennan MF. Results after pancreatic resection for metastatic lesions. Ann Surg Oncol. 2002;9(7):675-9. https://doi.org/10.1007/BF02574484
7. Fabre JM, Rouanet P, Dagues F, Blanck F, Baumel H, Domergue J. Various features and surgical approach of solitary pancreatic metastasis from renal cell carcinoma. Eur J Surg Oncol Eur Soc Surg Oncol Br Assoc Surg Oncol. 1995;21(6):683-6. https://doi.org/10.1016/s0748-7983(95)96079-1
8. Huscher CG, Mingoli A, Sgarzini G, Mercu A. Laparoscopic left nephrectomy with “en bloc” distal splenopancreatectomy. Ann Surg Oncol. 2012;19(2):693. https://doi.org/10.1245/s10434-011-1966-y
9. Abdul-Muhisin HM, Stern KL, Katairiya NN, Castle EP. Robot assisted “en bloc” radical nephrectomy, splenectomy and distal pancreatectomy for renal cell carcinoma: Case report and illustration of technique. J Robot Surg. 2016;10(4):375-8. https://doi.org/10.1007/s11701-016-0614-8
10. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91(13):1113-24. https://doi.org/10.1093/jnci/91.13.1113
11. van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, Bex A, de Gast G, Haanen JBAG, et al. Sunitinib for treatment of renal cancer.
of advanced renal cell cancer: Primary tumor response. Clin Cancer Res. 2008;14(8):2431–6. https://doi.org/10.1158/1078-0432.CCR-07-4089

12. Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 2017;67(6):507–24. https://doi.org/10.3322/caac.21411

13. Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal cell carcinoma. N Engl J Med. 2018;379(5):417–27. https://doi.org/10.1056/NEJMoa1803675

14. Antoine SG, Pfeifer Z, Carroll AM, Reece TB, Lloyd GL. Management of locally advanced renal cell carcinoma. AME Med J. 2021;6:5. https://doi.org/10.21037/amj-20-79

15. Moir JAG, Sen G, Saif R, Haugk B, French JJ. Isolated splenic metastasis from renal cell carcinoma: Case report and review. Case Rep Gastroenterol. 2011;5(1):166–71. https://doi.org/10.1159/000326963

16. dos Santos Romão D, Horvat N, Castro Gonçalves M, Abe ES, Dumarco RB, Viana PCC, et al. Isolated splenic metastases from renal cell carcinoma 11 years after surgery. Case Rep Med. 2019;2019:7480479. https://doi.org/10.1155/2019/7480479

17. Kaur Grewal S, Doley RP, Roy K, Singla M, Malhotra M, Bawa AS, et al. Isolated splenic metastasis from clear cell renal carcinoma—A case report. Int J Surg Case Rep. 2016;29:44–6. https://doi.org/https://doi.org/10.1016/j.ijsrcr.2016.10.045

18. Showalter SL, Hager E, Yeo CJ. Metastatic disease to the pancreas and spleen. Let us know how access to this document benefits you. 2008. Department of Surgery Faculty Papers. Paper 13.

19. Piskorz Ł, Mitura K, Olejniczak W, Misiak P, Jablonski S. Atypical locations of renal Cell carcinoma metastases to the pancreas and duodenum. Res Rep Urol. 2021;13:17–24. https://doi.org/10.2147/RUU.S290150.

20. González J, Gaynor JJ, Ciancio G. Renal cell carcinoma with or without tumor thrombus invading the liver, pancreas and duodenum. Cancers (Basel). 2021;13(7):1695. https://doi.org/10.3390/cancers13071695